Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide - Gilead Sciences

Drug Profile

Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide - Gilead Sciences

Alternative Names: Cobicistat/elvitegravir/emtricitabine/TAF; E/C/F/TAF; Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Emtricitabine/cobicistat/elvitegravir/tenofovir alafenamide; Genvoya; Tenofovir alafenamide/cobicistat/elvitegravir/emtricitabine

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Antiretrovirals; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Quinolones; Small molecules
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; HIV integrase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 01 Oct 2016 Gilead completes a phase III trial in HIV-1 infections in USA, Japan and Canada (PO) (NCT02071082)
  • 01 Oct 2016 Torii Pharmaceutical completes a pharmacokinetics trial in Healthy volunteers in Japan (JapicCTI-163307)
  • 01 Aug 2016 Gilead Sciences completes a phase II trial in HIV-1 infections (In adults, Treatment-naive) in USA and Puerto Rico (NCT01497899)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top